Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disproxil

- PMLiVE

Orexigen’s obesity pill Mysimba set for European approval

But sales of the treatment are only predicted to reach $200m by 2016

- PMLiVE

‘Major step forward’ as EMA recommends first stem cell therapy

But wants more clinical trial data to shore up orphan drug's marketing licence

- PMLiVE

Novo launches community health programme in New Jersey

Designed to support healthy lifestyle

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

- PMLiVE

France’s taxes make CEO search harder, says Sanofi chairman

Weinberg tells former minister Arnaud Montebourgthat that tax burden is a turn-off for senior executives

Sanofi reception

Sanofi and Evotec discuss high-level outsourcing alliance

Partnership to focus on cancer drug discovery

Sanofi reception

Sanofi’s Priftin cleared for latent tuberculosis in the US

FDA approves Priftin with isoniazid for patients aged two years and older

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

Sanofi reception

Sanofi plans 18 new product launches by 2020

Keen to reinstall faith of investors after firing CEO Viehbacher

- PMLiVE

EU approval for Gilead’s hep C combo Harvoni

Another boost for the company’s fast-growing Sovaldi franchise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links